Paramedic Papers

Home Other Single-dose aminoglycoside AKI risk in CKD

Other

Single-dose aminoglycoside AKI risk in CKD

The Safety of Single Aminoglycoside Dose in Emergency Departments (SAD-ED) Among Patients With and Without Chronic Kidney Disease: A Retrospective Cohort Study
Emergency Medicine Australasia · Added 4 August 2026

Retrospective cohort across four Australian hospitals — single-dose aminoglycosides caused AKI in 30.9% of CKD patients vs 13.4% without CKD (OR 2.88)

Study type
Cohort
Design
Retrospective cohort at four Australian tertiary hospitals
Participants
660 ED patients who received single-dose aminoglycosides
Main finding
AKI within 1 week occurred in 30.9% of CKD patients vs 13.4% without CKD (OR 2.88, 95% CI 1.76–4.71); CKD patients had more severe AKI (stage 2: 10.1% vs 2.6%)
Caveat
Retrospective design with confounding by indication — CKD patients were older with more comorbidities
Bottom line
Hypothesis-generating

Why it matters in Australia (High relevance). transferability — Australian study with direct clinical relevance — gentamicin is commonly given in ED/prehospital settings and CKD patients are at substantially higher risk

Learning goal

Weigh the renal risks of single-dose aminoglycosides in patients with chronic kidney disease before administration.

Open in dashboard Read the paper (DOI) PubMed

More

Related papers on Other